8-K/A: ABVC BioPharma Amends Convertible Note with Lind Global Fund II, LP, Introducing a Conversion Floor Price

ABVC BioPharma amended its convertible note with Lind Global Fund II, LP, establishing a $1.00 floor price for conversions and a potential cash payment to Lind if the floor price is triggered.

Summary

• ABVC BioPharma amended its secured convertible note with Lind Global Fund II, LP, originally issued on November 17, 2023.
• The amendment introduces a floor price of $1.00 for the conversion of the note into common stock.
• The conversion price is now the lesser of $3.50 or 90% of the average of the three lowest VWAPs during the 20 trading days prior to conversion, but not less than $1.00.
• For the first 180 days, conversions will be at the fixed price of $3.50, provided no event of default has occurred.
• If the conversion price is deemed to be the floor price of $1.00, ABVC BioPharma will also make a cash payment to Lind based on a specific formula.
• The formula for the cash payment is (A-B) x C, where A is the number of shares that would be issued at 90% of the lowest VWAP, B is the number of shares issued at the floor price, and C is the VWAP on the conversion date.
• The amendment was made to comply with Nasdaq requirements.

Sentiment

Score: 4

Explanation: The amendment introduces a floor price and potential cash payment, which are negative for the company. While the fixed price for the first 180 days is positive, the overall impact is likely negative for shareholders.

Positives

• The amendment provides clarity on the minimum conversion price, which could be beneficial for both parties.
• The fixed price of $3.50 for the first 180 days provides some stability for the conversion price.

Negatives

• The cash payment requirement if the floor price is triggered could be a financial burden for ABVC BioPharma.
• The floor price of $1.00 could result in significant dilution if the stock price falls below the fixed price of $3.50.

Risks

• The potential cash payment to Lind if the conversion price is at the floor price could strain ABVC BioPharma's finances.
• The conversion of the note at the floor price could lead to significant dilution of existing shareholders' equity.
• The stock price could fall below the fixed price of $3.50, triggering the floor price and the cash payment.

Future Outlook

The amendment to the convertible note introduces a floor price for conversions, which could impact future dilution and cash flow depending on the stock price and conversion decisions.

Management Comments

• Uttam Patil, Chief Executive Officer of ABVC BioPharma, signed the amendment on behalf of the company.

Industry Context

The use of convertible notes is a common financing method for biotech companies, especially those in early stages. The amendment to include a floor price is likely a result of negotiations with the investor and is not uncommon in such agreements.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small-cap biotech companies like ABVC BioPharma.
• The inclusion of a floor price is a protective measure for the investor, Lind Global Fund II, LP, ensuring a minimum conversion price.
• The specific terms of the note, such as the fixed price, variable price, and cash payment mechanism, are unique to this agreement and would need to be compared to similar deals to assess their favorability.
• Comparable companies in the biotech sector often use similar financing methods, but the specific terms can vary widely based on the company's financial health and the investor's risk appetite.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted at the floor price.
• The company's cash position could be impacted by the potential cash payment to Lind.
• The amendment could affect the company's ability to raise capital in the future.

Next Steps

• ABVC BioPharma will need to monitor its stock price to understand the potential impact of the floor price on conversions.
• The company will need to be prepared to make a cash payment to Lind if the conversion price is at the floor price.
• The company will need to manage the potential dilution from the conversion of the note and the exercise of the warrants.

Key Dates

Keywords

convertible note, amendment, floor price, conversion price, Lind Global Fund II, ABVC BioPharma, cash payment, warrant, dilution